Our in vitro and in vivo xenograft studies showed that overexpressing CCN2 significantly increased tumor cell survival, and suppression of CCN2 expression significantly increased drug sensitivity of osteosarcoma cells. This evidence concerns the gene CCN2 and osteosarcoma.